Oncology Institute’s (TOI) Buy Rating Reaffirmed at Needham & Company LLC

Oncology Institute (NASDAQ:TOI)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $5.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 79.86% from the stock’s current price.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Oncology Institute Stock Down 2.5%

Shares of TOI opened at $2.78 on Monday. The firm has a market cap of $273.50 million, a price-to-earnings ratio of -4.34 and a beta of 0.14. The business’s 50 day moving average is $3.10 and its two-hundred day moving average is $3.42. Oncology Institute has a 52-week low of $0.60 and a 52-week high of $4.88.

Insider Buying and Selling

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $3.77, for a total transaction of $50,265.41. Following the transaction, the director owned 683,721 shares of the company’s stock, valued at $2,577,628.17. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

A number of institutional investors have recently made changes to their positions in TOI. Kestra Advisory Services LLC acquired a new stake in shares of Oncology Institute during the 4th quarter valued at approximately $31,000. Pekin Hardy Strauss Inc. bought a new stake in Oncology Institute during the fourth quarter valued at $36,000. R Squared Ltd bought a new stake in Oncology Institute during the fourth quarter valued at $41,000. Prelude Capital Management LLC acquired a new stake in shares of Oncology Institute during the third quarter worth $41,000. Finally, ProShare Advisors LLC bought a new position in shares of Oncology Institute in the 2nd quarter worth about $25,000. 36.86% of the stock is currently owned by institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.